ALKERMES | ALKS - Net Income


ALKERMES reported $-66.48M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
ALKERMES USD -66.48M 115.82M Mar/2026
Amgen USD 1.82B 486M Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -93M 136M Mar/2026
J&J USD 5.24B 119M Mar/2026
Malin Corporation EUR -1.1M 2.2M Dec/2023
Merck USD -4.24B 7.2B Mar/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Otsuka Holdings JPY 98.35B 32.86B Mar/2026
Ovoca Bio EUR -765K 4.89M Jun/2025
Pfizer USD 2.69B 4.34B Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026